Effect of strontium ranelate on serum leptin and bone turnover markers in women with established postmenopausal osteoporosis.

ABSTRACT

OBJECTIVE: To assess the association between leptin levels and bone mineral density (BMD) and bone metabolism markers in postmenopausal women taking strontium ranelate. STUDY DESIGN: In this longitudinal uncontrolled study, postmenopausal osteoporotic women were administered strontium ranelate and categorized into 1 of 2 groups overweight and lean. BMD, serum leptin, bone-specific alkaline phosphatase (ALP) and urinary deoxypyridinoline (Dpd) were assessed at baseline, 6 and 12 months of the therapy. RESULTS: For all 47 women, leptin levels increased at the sixth month (p = 0.001) and 1 year after treatment (p = 0.001), Dpd levels decreased at the sixth month (p = 0.001) and 1 year after treatment (p = 0.003), but ALP levels did not change with respect to basal levels. Spine and hip BMD also increased at the end of 1 year (p = 0.01 and p = 0.001, respectively). For overweight women leptin levels increased 6 months and 1 year after treatment (p = 0.003 and p = 0.001, respectively). Dpd levels decreased significantly at the sixth month and at 1 year (p = 0.001 and p = 0.041), but ALP levels did not change. Hip and spine BMD also increased (p = 0.036 and p = 0.002). The lean group had similar serum results and BMD scores after treatment. CONCLUSION: Our data supports a positive effect of leptin on bone metabolism in favor of bone resorption inhibition in postmenopausal osteoporotic women on strontium treatment.